ATG Plus Cyclophosphamide To Prevent GVHD

A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) With ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
80 patients (estimated)
Sponsors
McMaster University
Collaborators
Sanofi, Ozmosis Research Inc., Cell Therapy Transplant Canada
Tags
Allogeneic Stem Cell Transplant, Post-Allogeneic Stem Cell Transplant, Randomization
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1918
NCT Identifier
NCT04202835

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.